5-MAPB Pellets – 50mg
€ 15,00 – € 220,00Price range: € 15,00 through € 220,00
5-MAPB Pellets 50mg are described as compressed research pellets containing nominally 50 mg of 5-MAPB hydrochloride per unit.
The named compound, 1-(benzofuran-5-yl)-N-methylpropan-2-amine, belongs to the substituted aminopropylbenzofuran family.
The neutral molecule has formula C12H15NO and molecular weight approximately 189.26 g/mol. The corresponding anhydrous hydrochloride has formula C12H16ClNO and molecular weight approximately 225.72 g/mol.
The supplied CAS number is 1354631-24-5, although its assignment has not been independently verified.
5-MAPB Pellets 50mg are presented in the source as research-only material for chemical identity assessment and analytical characterization.
The 50 mg label claim is not a verified finished-pellet assay. The source also claims ≥98% ingredient purity, independent testing, and batch traceability without supplying supporting records.
For 5-MAPB Pellets 50mg, ingredient purity, pellet mass, and active-ingredient content uniformity must be assessed separately.
The actual salt identity, stereochemical composition, excipients, dissolution characteristics, and storage stability remain unverified.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
5-MAPB Pellets 50mg – Benzofuran Research Material
5-MAPB Pellets 50mg – Product Overview
5-MAPB Pellets 50mg is the supplied catalog designation for compressed research pellets described as containing 5-MAPB hydrochloride.
The named compound belongs to the N-methylated substituted aminopropylbenzofuran family.
Its molecular framework contains a fused benzofuran ring system with an N-methylated aminopropyl substituent at the 5-position.
The source describes a nominal 50 mg ingredient content per pellet. This figure represents a label claim rather than an independently verified finished-product measurement.
5-MAPB Pellets 50mg are positioned for controlled laboratory investigation involving chemical identity, analytical documentation, and comparative structural characterization.
The source also describes high ingredient purity, standardized pellet composition, and independent analytical verification.
No actual Certificate of Analysis, finished-pellet assay, content-uniformity dataset, or batch-specific laboratory report was supplied.
Accordingly, the stated content, purity, physical presentation, and analytical performance remain unverified.
The pellets are not established as certified reference materials, validated quantitative calibrators, or approved pharmaceutical products.
Chemical Identity & Classification
5-MAPB Pellets 50mg are associated with 5-(2-methylaminopropyl)benzofuran, systematically named 1-(benzofuran-5-yl)-N-methylpropan-2-amine.
The named structure contains a benzofuran ring system and an N-methylated aminopropyl side chain.
The supplied chemical specifications are:
- Chemical abbreviation: 5-MAPB
- Chemical class: N-methylated substituted aminopropylbenzofuran
- Systematic name: 1-(Benzofuran-5-yl)-N-methylpropan-2-amine
- Reported CAS number: 1354631-24-5
- Neutral molecular formula: C12H15NO
- Neutral molecular weight: Approximately 189.26 g/mol
- Anhydrous hydrochloride formula: C12H16ClNO
- Anhydrous hydrochloride molecular weight: Approximately 225.72 g/mol
- Reported ingredient form: Hydrochloride
- Nominal ingredient content: 50 mg per pellet
- Finished-product presentation: Compressed pellets
The neutral molecular formula does not describe the complete hydrochloride composition.
The supplied CAS assignment has not been independently verified, and the actual salt form and stereochemical composition remain unresolved.
The earlier powder and capsule briefs reported a different CAS number. These identifiers should not be treated as interchangeable without chemical-registry verification.
For 5-MAPB Pellets 50mg, definitive identification requires records matching the actual ingredient structure and chemical form.
Public chemical-reference information can be reviewed through PubChem, with attention to the exact structure and salt designation.
Chemical & Physical Characteristics
The source describes 5-MAPB Pellets 50mg as compressed solid units containing a nominal amount of 5-MAPB HCl.
No finished-product inspection record, image verification, or physical-characterization report was supplied.
The source does not establish pellet dimensions, appearance, hardness, disintegration characteristics, or the physical state of the ingredient within the compressed matrix.
The chemical structure includes an N-methylated aminopropyl side chain attached to a fused benzofuran framework.
This distinguishes the named compound from related aminopropylbenzofurans that lack the N-methyl group or have different substitution positions.
The source identifies dissolution behavior, solubility, and stability as relevant analytical considerations.
However, no actual dissolution profile, validated solubility measurements, or extraction-recovery results were provided.
The pellet formulation may contain excipients, but their identities and quantities were not supplied.
Therefore, 5-MAPB Pellets 50mg cannot be assigned verified physical or dissolution properties solely from the stated ingredient identity.
The physical form also does not establish the ingredient’s purity or quantitative content.
Purity & Analytical Verification
The supplied source claims that 5-MAPB Pellets 50mg contain an ingredient with typical HPLC purity of at least 98%.
It also refers to mass spectrometry, NMR spectroscopy, and independent analytical verification.
No batch-specific chromatogram, mass spectrum, NMR spectrum, impurity report, or Certificate of Analysis was supplied.
The ingredient-purity claim therefore remains unverified.
Ingredient purity and finished-pellet content are distinct measurements.
A claim of 98% ingredient purity does not establish that each pellet contains 50 mg of the stated hydrochloride.
Similarly, uniform pellet mass does not establish uniform active-ingredient distribution.
For 5-MAPB Pellets 50mg, the source does not provide a finished-product assay, content-uniformity report, or validated quantitative recovery study.
The source mentions LC-MS/MS, HPLC, UV analysis, and spectroscopic characterization as relevant laboratory contexts.
These references do not demonstrate that a specific analytical method has been validated for the supplied product.
No certified reference-material documentation, assigned reference value, or measurement-uncertainty statement was provided.
Accordingly, the pellets should not be represented as certified quantitative reference standards.
Quality Control & Batch Integrity
The source states that 5-MAPB Pellets 50mg undergo batch tracking, independent laboratory testing, and controlled manufacturing.
It also claims pellet-weight consistency within approximately ±2% and reproducible dissolution performance.
These statements have not been substantiated by actual batch documentation.
No manufacturing record, independent laboratory report, pellet-weight dataset, dissolution study, or content-uniformity result was supplied.
A pellet-weight variation specification concerns the total mass of the finished unit.
It does not independently establish the amount or distribution of 5-MAPB within that unit.
For 5-MAPB Pellets 50mg, relevant quality documentation would need to distinguish ingredient identity, ingredient purity, total pellet mass, and actual ingredient content.
Other potentially relevant records include the excipient profile, batch identifier, residual-solvent findings, and available stability data.
The Research Use Only designation does not itself demonstrate certified quality, independent verification, or batch equivalence.
All source-reported quality claims should remain qualified until supported by appropriate documentation.
Safety, Handling & Laboratory Precautions
5-MAPB Pellets 50mg contain a compound associated with stimulant-class and serotonergic pharmacological concerns.
Related substances may present significant cardiovascular, neurological, and other toxicological hazards.
The source does not provide a verified product-specific Safety Data Sheet or comprehensive toxicological assessment.
Laboratory personnel should follow applicable institutional chemical-safety procedures, including restricted access, appropriate protective equipment, contamination prevention, and chemical-waste controls.
The compressed pellet format does not eliminate accidental-exposure concerns or establish a safe route of administration.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the finished-product composition and impurity profile are not independently confirmed, laboratory records should distinguish supplier claims from verified analytical findings.
5-MAPB Pellets 50mg are not intended for human or animal administration.
Accidental exposure and contamination incidents should be addressed under institutional emergency procedures.
Packaging, Labeling & Storage
The source describes 5-MAPB Pellets 50mg as supplied in resealable packaging.
No actual container specification, packaging-validation record, or shipment-condition report was provided.
The source recommends storage in a cool, dry environment protected from light and moisture.
A temperature range of approximately 2–8°C is suggested.
No validated finished-product stability study was supplied to establish that range as a verified storage requirement or to support a particular shelf life.
For 5-MAPB Pellets 50mg, inventory documentation should preserve the product designation, nominal ingredient content, batch information where available, receipt details, and relevant storage observations.
The source does not establish the long-term stability of the ingredient or the complete compressed formulation.
Storage and packaging requirements should therefore be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
Intended Research Use & Market Positioning
5-MAPB Pellets 50mg are positioned in the supplied material for laboratory contexts involving substituted benzofuran chemical identity, structural characterization, and comparative analytical profiling.
The compound’s fused benzofuran scaffold and N-methylated aminopropyl side chain are relevant distinguishing structural features.
The source also describes analytical interest in chromatographic behavior, spectroscopic signatures, and formulation-related measurements.
However, the actual pellet composition, ingredient content, and analytical suitability have not been independently established.
The supplied catalog identifies 5-MAPB Pellets 50mg as the product discussed here.
Related catalog entries include 5-MAPB Powder and 5-MAPB Capsules 100mg.
These are different product presentations with distinct formulation and analytical-documentation considerations.
For 5-MAPB Pellets 50mg, the ingredient-purity claim does not establish equivalence with powder or capsule formulations.
The catalog relationships also do not demonstrate certified reference-material status, identical batch composition, or validated quantitative performance.
Ordering, Availability & Fulfillment
The source describes international fulfillment, shipment tracking, protective packaging, and supporting customs documentation for 5-MAPB Pellets 50mg.
No current inventory record, carrier agreement, shipping authorization, or verified delivery information was supplied.
The source also claims compliance with IATA and DOT requirements.
No applicable transport classification, dangerous-goods assessment, shipping declaration, or other supporting compliance documentation was provided.
Accordingly, no claim is made that international shipment, customs clearance, or delivery is universally available or legally authorized.
5-MAPB may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutions must independently assess the legality of acquisition, possession, transport, importation, and exportation.
Research-only labeling does not establish an exemption from applicable law.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
5-MAPB Pellets 50mg are associated with a substituted aminopropylbenzofuran whose legal treatment may vary by jurisdiction.
The supplied information does not establish universal legal status, regulatory authorization, or an exemption for laboratory acquisition.
Institutions remain responsible for identifying applicable laws and obtaining any required permissions.
No medical approval, consumer-use authorization, certified reference-material status, or validated quantitative performance is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.